Marinomed Biotech Aktie
WKN DE: A2N9MM / ISIN: ATMARINOMED6
|
18.12.2023 08:30:52
|
EQS-Adhoc: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) announces that the Company considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. The Company is continuously evaluating the business to enable the best possible future growth. Regulatory changes in the coming year will also be included in the evaluation, which are expected to have a positive impact on the Company's business, particularly with regard to Carragelose products. The evaluation process may include strategic partnerships and the consideration of transferring the Carragelose portfolio to a partner that could maximize its value enabling the Company to increase its focus on the Marinosolv platform. +++ End of the ad hoc announcement +++ End of Inside Information
18-Dec-2023 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 1798437 |
| End of Announcement | EQS News Service |
|
|
1798437 18-Dec-2023 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Marinomed Biotech AGmehr Nachrichten
|
09.10.25 |
Donnerstagshandel in Wien: ATX Prime zum Ende des Donnerstagshandels im Plus (finanzen.at) | |
|
09.10.25 |
ATX Prime-Handel aktuell: ATX Prime verbucht nachmittags Zuschläge (finanzen.at) | |
|
09.10.25 |
Pluszeichen in Wien: Anleger lassen ATX Prime am Donnerstagmittag steigen (finanzen.at) | |
|
09.10.25 |
Wiener Börse-Handel: ATX Prime zum Start im Aufwind (finanzen.at) | |
|
08.10.25 |
Angespannte Stimmung in Wien: ATX Prime letztendlich in der Verlustzone (finanzen.at) | |
|
08.10.25 |
Börse Wien: ATX Prime legt am Nachmittag zu (finanzen.at) | |
|
08.10.25 |
Börse Wien: Börsianer lassen ATX Prime mittags steigen (finanzen.at) | |
|
08.10.25 |
Gewinne in Wien: ATX Prime-Anleger greifen zum Start des Mittwochshandels zu (finanzen.at) |
Analysen zu Marinomed Biotech AGmehr Analysen
| 19.09.23 | Marinomed Biotech kaufen | Erste Group Bank | |
| 05.04.23 | Marinomed Biotech kaufen | Erste Group Bank | |
| 20.09.22 | Marinomed Biotech kaufen | Erste Group Bank | |
| 05.04.22 | Marinomed Biotech kaufen | Erste Group Bank | |
| 14.09.21 | Marinomed Biotech kaufen | Erste Group Bank |
Aktien in diesem Artikel
| Marinomed Biotech AG | 19,70 | -0,76% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.